Establishing a Position as a Top Player in the iPS Cell and Regenerative Medicine Market
First written in FY2017. 21 of 22 entries say "Restated". Latest entry: FY2026-H1.
1 other company's latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「In this growth market, the group aims to maximize corporate value by focusing its management resources on developing an innovative pipeline of regenerative medicine and other products and addressing unmet medical needs.」
The company has reaffirmed its policy of focusing management resources on its regenerative medicine and other product pipeline and aiming to maximize corporate value in this growth market. - FY2025-H1RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve sustainable growth from the short to medium to long term.」
The company has reaffirmed its policy of pursuing sustainable growth in fields including regenerative medicine by combining the Research Support Business and the Medical Business. - FY2024-Q3RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its policy of pursuing continuous growth in fields including regenerative medicine by combining the Research Support Business and the Medical Business. - FY2024-Q2RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its policy of pursuing sustained growth in fields including regenerative medicine by combining the Research Support Business and the Medical Business. - FY2024-Q1RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its policy of pursuing growth through a two-business structure consisting of the Research Support Business as a short- to medium-term focus and the Medical Business as a medium- to long-term growth area. - FY2023-Q3RestatedAnnual report
「Accordingly, the company positions regenerative medicine as a medium- to long-term growth business and aims to obtain marketing authorization at an early stage.」
The company has reaffirmed its policy of positioning regenerative medicine as a medium- to long-term growth business and aiming to obtain marketing authorization at an early stage. - FY2023-Q2RestatedAnnual report
「Accordingly, the company positions regenerative medicine as a medium- to long-term growth business and aims to obtain marketing authorization at an early stage.」
The company has reaffirmed its policy of positioning regenerative medicine as a medium- to long-term growth business and aiming to obtain marketing authorization at an early stage. - FY2023-Q1RestatedAnnual report
「Accordingly, the company positions regenerative medicine as a medium- to long-term growth business and aims to obtain marketing authorization at an early stage.」
The company has reaffirmed its policy of positioning regenerative medicine as a medium- to long-term growth business and expanding the business through the early acquisition of marketing authorization. - FY2022-Q3RestatedAnnual report
「Accordingly, the company positions regenerative medicine as a medium- to long-term growth business and aims to obtain marketing authorization at an early stage.」
The company has reaffirmed its policy of positioning regenerative medicine as a medium- to long-term growth business and aiming to obtain marketing authorization at an early stage. - FY2022-Q1RestatedAnnual report
「Accordingly, the company positions regenerative medicine as a medium- to long-term growth business and aims to obtain marketing authorization at an early stage.」
The company has reaffirmed its policy of positioning regenerative medicine as a medium- to long-term growth business and aiming to obtain marketing authorization at an early stage. - FY2021RestatedAnnual report
「The company will actively invest in these regenerative medicine products as medium- to long-term growth businesses and aim to obtain marketing authorization at an early stage.」
The company has reaffirmed its policy of positioning regenerative medicine as a medium- to long-term growth area and expanding the business through active investment and early marketing authorization. - FY2021-Q3RestatedAnnual report
「Accordingly, the company positions regenerative medicine as a medium- to long-term growth business and aims to obtain marketing authorization at an early stage.」
The company has reaffirmed its policy of positioning regenerative medicine as a medium- to long-term growth area and aiming to obtain marketing authorization at an early stage. - FY2021-Q2RestatedAnnual report
「Accordingly, the company positions regenerative medicine as a medium- to long-term growth business and aims to obtain marketing authorization at an early stage.」
The company has reaffirmed its policy of positioning regenerative medicine as a medium- to long-term growth area and aiming to obtain marketing authorization at an early stage. - FY2021-Q1RestatedAnnual report
「Accordingly, the company positions regenerative medicine as a medium- to long-term growth business and aims to obtain marketing authorization at an early stage.」
The company has reaffirmed its policy of positioning regenerative medicine as a medium- to long-term growth area and aiming to obtain marketing authorization at an early stage. - FY2020RestatedAnnual report
「The company will actively invest in these regenerative medicine products as medium- to long-term growth businesses and aim to obtain marketing authorization at an early stage.」
The company has reaffirmed its policy of aiming to become a market leader, with the Research Support Business as a short- to medium-term focus and the Medical Business, including regenerative medicine, as a medium- to long-term growth area. - FY2019-Q3RestatedAnnual report
「Against this business backdrop, the Group is developing its research support business, which provides research reagents and drug discovery support services related to iPS cells, as a short- to medium-term business pillar. As a medium- to long-term growth strategy, it is actively investing in the medical business, which is expected to address a huge market, with the aim of becoming a market leader in this field.」
The company has reaffirmed its policy of aiming to become a market leader in the iPS cell and regenerative medicine fields through resource allocation to the Research Support Business and the Medical Business. - FY2019-Q2RestatedAnnual report
「Against this business backdrop, the Group is developing its research support business, which provides research reagents and drug discovery support services related to iPS cells, as a short- to medium-term business pillar. As a medium- to long-term growth strategy, it is actively investing in the medical business, which is expected to address a huge market, with the aim of becoming a market leader in this field.」
The company has reaffirmed its policy of aiming to become a market leader in the iPS cell and regenerative medicine fields through resource allocation to the Research Support Business and the Medical Business. - FY2019-Q1RestatedAnnual report
「We aim to become a market leader in this field by developing the Research Support Business, which provides iPS cell-related research reagents and drug discovery support services as a short- to medium-term business pillar, and by actively investing in the Medical Business, which is expected to address a huge market as a medium- to long-term growth strategy.」
The company has reaffirmed its policy of actively investing in the Research Support Business as a short- to medium-term pillar and the Medical Business as a medium- to long-term growth strategy, with the aim of becoming a market leader. - FY2018RestatedAnnual report
「The company aims to become a market leader by promoting the Research Support Business as a short- to medium-term business pillar and actively investing in the Medical Business, where a huge market is expected, as a medium- to long-term growth strategy.」
The company has reaffirmed its policy of aiming to become a market leader, with the Research Support Business as a short- to medium-term focus and the Medical Business as a medium- to long-term growth strategy. - FY2018-Q3RestatedAnnual report
「We aim to become a market leader in this field by developing the Research Support Business, which provides iPS cell-related research reagents and drug discovery support services as a short- to medium-term business pillar, and by actively investing in the Medical Business, which is expected to address a huge market as a medium- to long-term growth strategy.」
The company has reaffirmed its policy of investing actively in the Research Support Business as a short- to medium-term pillar and the Medical Business as a medium- to long-term growth strategy, with the aim of becoming a market leader. - FY2018-Q1RestatedAnnual report
「The Medical Business is currently in the research and development phase, but as a huge market is expected over the medium to long term as described above, the company will actively promote research and development and aim to become a market leader in this field.」
The company has reaffirmed its policy of aiming to become a market leader in the Medical Business through active research and development. - FY2017First statedAnnual report
「In this context, the company aims to establish a leading position and achieve substantial growth alongside the market by pursuing an aggressive management policy that keeps it ahead of competitors.」
The goal of becoming a leading player in the iPS cell research and regenerative medicine markets was identified for the first time as a standalone management policy.